Journal of Antimicrobial Chemotherapy, Vol 40, 797-802, Copyright © 1997 by The British Society for Antimicrobial Chemotherapy
KP Klugman and T Capper
The in-vitro activity of the methoxyquinolone moxifloxacin (Bay 12- 8039)
was compared with that of ciprofloxacin, levofloxacin, norfloxacin,
ofloxacin and sparfloxacin against 220 pneumococcal isolates. Moxifloxacin
was more active than the comparator quinolones against all strains
including 60 strains intermediately susceptible to penicillin, 60 strains
resistant to penicillin and 40 strains resistant to the macrolides. When
the activity of the moxifloxacin was compared with that of oral
beta-lactams, macrolides and azalides used to treat respiratory infections,
the drug was as active as penicillin, co- amoxiclav and cefuroxime against
penicillin-susceptible strains and as active as clarithromycin and
erythromycin against macrolide-susceptible strains. The drug was more
active than any oral beta-lactam agent against intermediate or fully
penicillin-resistant strains and more active than any of the macrolides
against macrolide-resistant strains. In time-kill assay studies,
moxifloxacin showed concentration-dependent killing at about the MIC. The
mean log10 reduction in colony count for nine strains each tested in
triplicate was 1.2 log10 after 6 h of incubation at 2 x MIC of
moxifloxacin. The log10 killing at 6 h increased to 2.74 log10 at 4 x MIC,
3.75 log10 at 8 x MIC and 4.17 log10 at 16 x MIC. Because of the enhanced
potency of this quinolone against pneumococci, concentrations of 8 x MIC90
were achieved at 0.48- 0.96 mg/L. These data suggest that orally
administered moxifloxacin is likely to be highly active at physiological
concentrations against penicillin- and macrolide-resistant pneumococci.
ORIGINAL ARTICLES
Concentration-dependent killing of antibiotic-resistant pneumococci by the methoxyquinolone moxifloxacin
MRC/SAIMR/WITS Pneumococcal Diseases Research Unit, Johannesburg, South Africa. 174klug@mail.saimr.wits.ac.za
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Soman, D. Honeybourne, J. Andrews, G. Jevons, and R. Wise Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy J. Antimicrob. Chemother., December 1, 1999; 44(6): 835 - 838. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Müller, H. Staß, M. Brunner, J. G. Möller, E. Lackner, and H. G. Eichler Penetration of Moxifloxacin into Peripheral Compartments in Humans Antimicrob. Agents Chemother., October 1, 1999; 43(10): 2345 - 2349. [Abstract] [Full Text]
|
|
|
|
|
|
C. Østergaard, T. Klitmøller Sørensen, J. Dahl Knudsen, and N. Frimodt-Møller Evaluation of Moxifloxacin, a New 8-Methoxyquinolone, for Treatment of Meningitis Caused by a PenicillinResistant Pneumococcus in Rabbits Antimicrob. Agents Chemother., July 1, 1998; 42(7): 1706 - 1712. [Abstract] [Full Text]
|
|